Search

Introduction: Acute Myocardial Infarction (AMI) is one of the main causes of hospitalizations, and consequently, of death in the modern world. Type 4 is the AMI related to stent thrombosis/restenosis in patients who have previously undergone to a endovascular treatment with stent implantation to restore coronary blood flow. Objectives: Investigate and collect data on the epidemiological and clinical profile, risk factors and use of patients' medications and the incidence of stent restenosis/thrombosis, type of stent used (pharmacological or not) and affected arteries in those treated at the Hemodynamics of a large hospital in the North of Paraná. Methodology: Quantitative, retrospective, descriptive, integrative and observational research, through analysis of the medical records of patients undergoing coronary angioplasty due to stent thrombosis/restenosis, in the period from July to December 2022.Result: A rate of 4.1% was found of CTA procedures performed in the service due to stent thrombosis/restenosis, 93.75% over 51 years old, 75% male, 81% with drug-eluting stent, with 93.75% of patients with at least 3 risk factors; 87.5% being hypertensive, followed by 62.5% smokers, 56.5% dyslipidemia, 50% diabetic and 25% sedentary; 62.5% admitted with unstable angina, 37.5% requiring ICU admission, and 12.5% deaths. Argument: as the data collected, there was agreement between the study and those found in the scientific literature, where: the prevalence of restenosis is higher than stent thrombosis, that SAH was the main risk factor in both groups and gender, a strong relationship between risk factor and restenosis and suspected strong association between poor medication adherence and event. Conclusion: This study, carried out by collecting data through analysis of medical records, showed agreement with data from the scientific literature found. With limitations to the study, such as the retrospective analysis that did not allow evaluating conditions other than those provided in the medical records. It is suggested that strategies be developed through continued work, with the possibility of collecting other pertinent data such as medication adherence and other risk factors involved, to reduce events, with an impact not only on mortality but also on the quality of life of these patients. [ABSTRACT FROM AUTHOR]

Introduction: Stent restenosis remains a clinical challenge for patients with ischemic heart disease, since it is associated with repeated coronary interventions as well as higher hospitalization rates and medical costs. Inflammation plays a significant role. Although an association between stent restenosis, increased C-reactive protein (CRP) and decreased albumin levels has been previously reported, no studies have investigated the ability of the CRP/albumin ratio to predict stent restenosis., Methods: This retrospective study included 448 patients who had previously undergone primary percutaneous coronary intervention and who were referred for subsequent reintervention due to recurrence of anginal symptoms. The study population was divided into two groups based on whether the patient had developed stent restenosis. They were then stratified into three groups according to their CRP/albumin ratio., Results: Out of 448 patients, stent restenosis was observed in 24.5% (n=110), as determined by coronary angiography. Patients with stent restenosis had a higher CRP/albumin ratio, greater platelet distribution width (PDW), higher CRP levels, and lower levels of both high-density lipoprotein (HDL) cholesterol and serum albumin. The CRP/albumin ratio (OR: 2.289, 95% CI: 1.056-4.959; p=0.036), stent diameter, PDW and HDL cholesterol levels were found to be independent predictors of stent restenosis. A ROC curve comparison demonstrated that the CRP/albumin ratio was a better predictor of restenosis than either albumin and CRP individually, but it was not better than PDW and HDL cholesterol., Conclusion: As a novel inflammation-based risk score, the CRP/albumin ratio may be an easily accessible marker for assessment of stent restenosis risk., (Copyright © 2019 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.)